Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Shares Outstanding (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Shares Outstanding data on record, last reported at $81.5 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 4.85% year-over-year to $81.5 million; the TTM value through Dec 2025 reached $81.5 million, up 4.85%, while the annual FY2025 figure was $81.5 million, 4.85% up from the prior year.
  • Shares Outstanding reached $81.5 million in Q4 2025 per PTCT's latest filing, up from $79.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $81.5 million in Q4 2025 and bottomed at $70.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $74.9 million, with a median of $75.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: increased 12.19% in 2021, then rose 1.32% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $70.8 million in 2021, then rose by 3.21% to $73.1 million in 2022, then rose by 3.56% to $75.7 million in 2023, then grew by 2.64% to $77.7 million in 2024, then increased by 4.85% to $81.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $81.5 million in Q4 2025, $79.9 million in Q3 2025, and $79.4 million in Q2 2025.